Hoth Therapeutics and Aronnax sign master services agreement for HT-KIT

Hoth Therapeutics has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT research to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells has demonstrated that HT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive. The effect of a single dose lasted for about two weeks, while reduced KIT expression lasted for 7 days. This result also demonstrated HT-KIT’s potential to reduce KIT expression using GIST cells and kill within 48 and 72 hours along with lower KIT expression in AML cells over 72 hours. HT-KIT is being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA. This study will provide Hoth key metrics in both max dose and range finding elements which will help formulate its proposed clinical trial.